Increasingly, employees are telling their employers that they want access to these medications, and many employers would like to offer plans that cover them
Why does the origin story of compounded versions matter
In fact, the evidence became so compelling that in August of last year, the FDA approved semaglutide (Wegovy) for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis, based on the phase 3 ESSENCE trial
24.2% weight loss at 48 weeks (Phase 2)
Still, this factor varies from person to person, so such an effect shouldnt be universally expected
Talk to your health care professional about any side effect that continues to bother you or doesn't go away